Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR2 gene amplification and clinicopathological features in gastric cancer

12 Jan 2012

Abstract excerpt

BACKGROUND: Frequency of FGFR2 amplification, its clinicopathological features, and the results of high-throughput screening assays in a large cohort of gastric clinical samples remain largely unclear. METHODS: Drug sensitivity to a fibroblast growth factor receptor (FGFR) inhibitor was evaluated in vitro. The gene amplification of the FGFRs in formalin-fixed, paraffin-embedded (FFPE) gastric cancer tissues was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eosinophilic Disorders and Syndromes
Share to Fibroblast Growth Factor Research
Share to Gastrointestinal Tumor Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22240789
DOI: 10.1038/bjc.2011.603

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR2 gene amplification and clinicopathological features in gastric cancerPMID 22240789Read ↗

FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.Semantic proximity Read ↗

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre studySemantic proximity Read ↗

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.Semantic proximity Read ↗

Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridizationSemantic proximity Read ↗

Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancerSemantic proximity Read ↗

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric CancerSemantic proximity Read ↗

FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohortSemantic proximity Read ↗

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinomaSemantic proximity Read ↗

A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurementsSemantic proximity Read ↗

<i>MET</i> amplification as a potential therapeutic target in gastric cancerSemantic proximity Read ↗

Acquired FGFR2 mutation leads resistance to pemigatinib in a patient with FGFR2-driven Borrmann type IV gastric cancer.Semantic proximity Read ↗

High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.